Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Items 201–300 of 1,001
The use of direct oral anticoagulants in inherited thrombophilia
Skelley, J. W., White, C. W., & Thomason, A. R. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1428-2 · Cited by 76
Erdoes, G., de Arroyabe, B. M. L., Bolliger, D., Ahmed, A. B., Koster, A., Agarwal, S., Boer, C., & von Heymann, C. (2018) · Anaesthesia · doi:10.1111/anae.14425 · Cited by 65
New oral anticoagulant agents – general features and outcomes in subsets of patients
Schulman, S. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0803 · Cited by 71
“edoxaban, had both the phase III trials on SPAF (13) and on treatment of VTE published (14).”
BackgroundMoigne, E. L., Timsit, S., Salem, D. B., Didier, R. J., Jobic, Y., Paleiron, N., Mao, R. L., Joseph, T., Hoffmann, C., Dion, A., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3485 · Cited by 72
Direct oral anticoagulants in patients with liver cirrhosis: A systematic review
Hoolwerf, E. W., Kraaijpoel, N., Buller, H. R., & van Es, N. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.08.011 · Cited by 71
Wang, C., Wu, V. C., Kuo, C., Chu, P., Tseng, H., Wen, M., & Chang, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009263 · Cited by 70
Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
Kustos, S. A., & Fasinu, P. S. (2019) · Medicines · doi:10.3390/medicines6040103 · Cited by 73
Larsen, T. B., Nielsen, P. B., Skjøth, F., Rasmussen, L. H., & Lip, G. Y. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114445 · Cited by 64
Elshafei, M. N., Mohamed, M. F. H., El‐Bardissy, A., Ahmed, M. B., Abdallah, I. M. H., Elewa, H. F., & Danjuma, M. I.-M. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02179-4 · Cited by 72
Mendell, J., Johnson, L., & Chen, S. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.550 · Cited by 68
“Subjects with severe hepatic impairment were not included in the study, consistent with exclusion criteria for the phase 3 studies for ENGAGE AF-TIMI 48 and Hokusai-VTE.(2,3) Subjects in all 4 treatment cohorts were excluded if they tested positive for human immunodeficiency virus antibody, used alcohol or drugs of ab…”
MethodGu, Z., Zhou, L., Shen, L., Zhang, C., Pu, J., Lin, H., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00348 · Cited by 64
“…1 and Table S1) (Connolly et al., 2009; Schulman et al., 2009, 2013, 2014; EINSTEIN Investigators et al., 2010; Granger et al., 2011; Patel et al., 2011; EINSTEIN–PE Investigators et al., 2012; Hori et al., 2012; Agnelli et al., 2013; Giugliano et al., 2013; HokusaiVTE Investigators et al., 2013).”
BackgroundRezuş, E., Tamba, B.-I., Bădescu, M. C., Popescu, D., Bratoiu, I., & Rezuș, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136801 · Cited by 67
Beyer‐Westendorf, J., Michalski, F., Tittl, L., Hauswald-Dörschel, S., & Marten, S. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30111-9 · Cited by 61
Spronk, H. M. H., Padró, T., Siland, J. E., Prochaska, J. H., Winters, J., van der Wal, A. C., Posthuma, J. J., Lowe, G. D. O., D’Alessandro, E., Wenzel, P., et al. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-07-0492 · Cited by 75
“Non-VKA oral anticoagulants (NOAC) have shown to be at least as effective and safer as VKA in large trials, 91,168 – 170 and are now changing clinical practice.”
Rossel, A., Robert‐Ebadi, H., Combescure, C., Grosgurin, O., Stirnemann, J., Addeo, A., Garin, N., Agoritsas, T., Reny, J., & Marti, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213940 · Cited by 66
Oral Anticoagulation in the Elderly and Frail
Bauersachs, R. M., & Herold, J. (2020) · Hämostaseologie · doi:10.1055/s-0040-1701476 · Cited by 68
Johnston, S. (2016) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.12.010 · Cited by 73
Hill, K. M., Sucha, E., Rhodes, E., Carrier, M., Garg, A. X., Harel, Z., Hundemer, G. L., Clark, E. G., Knoll, G. A., McArthur, E., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.1835 · Cited by 60
Goto, S., Haas, S. K., Ageno, W., Goldhaber, S. Z., Turpie, A. G. G., Weitz, J. I., Angchaisuksiri, P., Nielsen, J. D., Kayani, G., Farjat, A. E., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22886 · Cited by 61
Skaistis, J., & Tagami, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137444 · Cited by 66
A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease
Parker, K., Hartemink, J., Saha, A., Mitra, R., Lewis, P. J., Power, A. J., Choudhuri, S., Mitra, S., & Thachil, J. V. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01413-x · Cited by 71
Fuji, T., Wang, C.-J., Fujita, S., Kawai, Y., Kimura, T., & Tachibana, S. (2014) · The Journal of Arthroplasty · doi:10.1016/j.arth.2014.05.029 · Cited by 58
“Previous phase II studies in patients undergoing THA [9] and TKA [13] demonstrated that edoxaban was safe and effective for thromboprophylaxis across a wide range of doses.”
BackgroundVenous thromboembolism in the elderly: A narrative review
Tritschler, T., & Aujesky, D. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.015 · Cited by 68
Gómez-Outes, A., Lecumberri, R., Suárez-Gea, M. L., Terleira-Fernández, A.-I., Monreal, M., & Vargas-Castrillón, E. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415575154 · Cited by 57
“10 Case fatality VTE rate (95%CI), % 16 (7-28) 4 (0.”
Yaghi, S. R., Saldanha, I. J., Misquith, C., Zaidat, B., Shah, A., Joudi, K., Persaud, B., Khalek, F. A., Shu, L., de Havenon, A., et al. (2022) · Stroke · doi:10.1161/strokeaha.122.039579 · Cited by 58
Caterina, R. D., & Lip, G. Y. H. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1102-5 · Cited by 57
“Using the lower doses of edoxaban, there was no relationship found between body weight and incidence of VTE or major bleeding in patients [25, 26].”
BackgroundYamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2018) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872618799993 · Cited by 67
“001 Length of hospital stay (days) 17 (12-24) 15 (11-20) 17 (12-25) <0.”
Singer, A. J., Thode, H. C., & Peacock, W. F. (2016) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.15.096 · Cited by 63
“, rivaroxaban, apixaban, dabigatran, edoxaban).(16-21) Additionally, changes in the healthcare system and financial constraints are leading to a decrease in the number of patients admitted, especially those admitted for short periods.”
BackgroundHaas, S. K., Ageno, W., Angchaisuksiri, P., Bounameaux, H., Nielsen, J. D., Goldhaber, S. Z., Goto, S., Kayani, G., Mantovani, L. G., Prandoni, P., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-04-0335 · Cited by 65
Ovarian Vein Thrombosis: A Narrative Review
Riva, N., & Calleja‐Agius, J. (2020) · Hämostaseologie · doi:10.1055/a-1306-4327 · Cited by 63
Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus
Carrier, M., Blais, N., Crowther, M. A., Kavan, P., Gal, G. L., Moodley, O., Shivakumar, S., Suryanarayan, D., Tagalakis, V., Wu, C. M., et al. (2021) · Current Oncology · doi:10.3390/curroncol28060453 · Cited by 62
Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020
Iyer, G. S., Tesfaye, H., Khan, N. F., Zakoul, H., & Bykov, K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.4059 · Cited by 61
Antithrombotic Management of Venous Thromboembolism
Renner, E., & Barnes, G. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.070 · Cited by 60
Carlin, S., Cuker, A. C., Gatt, A., Gendron, N., Hernández–Gea, V., Meijer, K., Siegal, D. M., Stanworth, S. J., Lisman, T., & Roberts, L. N. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.05.023 · Cited by 67
Nakamura, M., Wang, Y. Q., Wang, C., Oh, D., Yin, W., Kimura, T., Miyazaki, K., Abe, K., Mercuri, M. F., Lee, L. H., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13055 · Cited by 55
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Robertson, L., Kesteven, P. J., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub2 · Cited by 62
Mearns, E. S., Kohn, C. G., Song, J.-S., Hawthorne, J., Meng, J., White, C. M., Raut, M. K., Schein, J. R., & Coleman, C. I. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.035 · Cited by 63
Acute treatment of venous thromboembolism
Becattini, C., & Agnelli, G. (2020) · Blood · doi:10.1182/blood.2019001881 · Cited by 64
Cerebral Venous Thrombosis: We Should Ask the Right Questions to Get Better Answers
Field, T. S., & Hill, M. D. (2019) · Stroke · doi:10.1161/strokeaha.119.025334 · Cited by 57
Direct oral anticoagulant considerations in solid organ transplantation: A review
Salerno, D. M., Tsapepas, D. S., Papachristos, A., Chang, J., Martin, S. T., Hardy, M. A., & McKeen, J. T. (2016) · Clinical Transplantation · doi:10.1111/ctr.12873 · Cited by 55
Raskob, G. E., Buller, H. R., GROSSO, M. A., Zhang, G., Winters, S. M., Cohen, A. T., & Nisio, M. D. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-11-0830 · Cited by 56
Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors
Liu, M., Zaman, K., & Fortenberry, Y. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083897 · Cited by 54
Xu, Y., & Siegal, D. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15466 · Cited by 66
Weinberg, E. M., Palecki, J., & Reddy, K. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679934 · Cited by 56
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
Bikdeli, B., Tajrishi, F. Z., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Lippi, G., Siegal, D. M., Eikelboom, J. W., Monréal, M., Jiménez, D., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1292 · Cited by 61
Kaneda, K., Yamashita, Y., Morimoto, T., Chatani, R., Nishimoto, Y., Ikeda, N., Kobayashi, Y., Ikeda, S., Kim, K., Inoko, M., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.08.007 · Cited by 58
Minno, M. N. D. D., Lupoli, R., Minno, A. D., Ambrosino, P., Scalera, A., & Dentali, F. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.982064 · Cited by 56
Minimizing the Risk of Bleeding with NOACs in the Elderly
Kundu, A., Sardar, P., Chatterjee, S., Aronow, W. S., Owan, T., & Ryan, J. J. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0376-z · Cited by 58
“[29].”
Burr, N. E., Lummis, K., Sood, R., Kane, J. S., & Subramanian, V. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30162-5 · Cited by 60
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
Stefano, V. D., Finazzi, G., & Barbui, T. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0101-8 · Cited by 58
Bertoletti, L., & Humbert, M. J. C. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.10.005 · Cited by 53
Novel anticoagulants: general overview and practical considerations for dental practitioners
Elad, S., Marshall, J., Meyerowitz, C., & Connolly, G. (2015) · Oral Diseases · doi:10.1111/odi.12371 · Cited by 57
Drug-drug interactions of non-vitamin K oral anticoagulants
Voukalis, C., Lip, G. Y. H., & Shantsila, E. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1225037 · Cited by 56
“[108] evaluated whether enoxaparin followed by edoxaban may be an alternative to LMWH followed by warfarin for treatment of venous thromboembolism.”
BackgroundThe use of direct oral anticoagulants in chronic kidney disease
Parker, K., & Thachil, J. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15564 · Cited by 54
“…Journal of Haematology, 2018, 183, 170–184 observational study of patients with AF prescribed rivaroxaban, more than one-third of patients with CrCl <50 ml/min received the standard dose of 20 mg daily, whereas 15% of patients with CrCl > 50 ml/min received the reduced dose (Camm et al, 2016).”
Brunetti, N. D., Gesuete, E., Gennaro, L. D., Correale, M., Caldarola, P., Gaglione, A., & Biase, M. D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.168 · Cited by 54
Huang, H., Liu, P. P., Hsu, J., Lin, S., Peng, C. C., Wang, J., & Loh, C. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz952 · Cited by 52
The role of factor Xa inhibitors in venous thromboembolism treatment
Cabral, K. P., & Ansell, J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s39726 · Cited by 50
Harder, S. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-22 · Cited by 54
Recent advances in the management of pulmonary embolism: focus on the critically ill patients
Meyer, G., Vieillard‐Baron, A., & Planquette, B. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0122-z · Cited by 63
Drouet, L. O., Sollier, C. B. D., Steiner, T., & Purrucker, J. C. (2016) · International Journal of Stroke · doi:10.1177/1747493016659671 · Cited by 57
Edoxaban: A direct oral anticoagulant
Poulakos, M. N., Walker, J. N., Baig, U., & David, T. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150821 · Cited by 57
“The Hokusai-VTE study investigators (Büller et al.31) conducted a Phase III randomized, double-blind, double-dummy trial comparing edoxaban with warfarin for the prevention of recurrent symptomatic VTE.”
BackgroundMethodInfluentialLeentjens, J., Peters, M. J. L., Esselink, A. C., Smulders, Y. M., & Kramers, C. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13340 · Cited by 60
Wu, T., Lv, C., Wu, L., Chen, W., Lv, M., Jiang, S., & Zhang, J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10448-2 · Cited by 54
Jönsson, S., Simonsson, U. S. H., Miller, R., & Karlsson, M. O. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.541 · Cited by 48
“The current dose recommendation includes a dose reduction by 50% in patients with moderate renal impairment and has been shown to be safe and efficacious in this subpopulation.(2,3) On the basis of the results in the current analysis, that is, that renal function has minor or no influence on the concentration ratios (…”
BackgroundGodin, R., Marcoux, V., & Tagalakis, V. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.05.001 · Cited by 53
Anticoagulation in chronic kidney disease: current status and future perspectives
Jones, A. P., Swan, D., Lisman, T., Barnes, G. D., & Thachil, J. V. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.020 · Cited by 62
Herzog, E., Kaspereit, F., Krege, W., Doerr, B., Mueller‐Cohrs, J., Pragst, I., MORISHIMA, Y., & Dickneite, G. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000520 · Cited by 49
Management of venous thromboembolism: an update
Piran, S., & Schulman, S. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0107-z · Cited by 53
“Trial Name [Ref] RE-COVER [15] RE-COVER II [16] EINSTEIN-DVT [17] EINSTEIN-PE [18] AMPLIFY [19] Hokusai-VTE [20]”
BackgroundMethodInfluentialMilling, T. J., & Frontera, J. A. (2017) · PubMed · Cited by 63
Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis
Montiel, F. S., Ghazvinian, R., Gottsäter, A., & Elf, J. L. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0149-x · Cited by 52
Lutsey, P. L., Zakai, N. A., MacLehose, R. F., Norby, F. L., Walker, R. F., Roetker, N. S., Adam, T. J., & Alonso, A. (2019) · British Journal of Haematology · doi:10.1111/bjh.15857 · Cited by 47
Larsen, T. B., Skjøth, F., Kjældgaard, J. N., Lip, G. Y. H., Nielsen, P. B., & Søgaard, M. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30054-6 · Cited by 50
Pharmacology and mechanisms of action of new oral anticoagulants
Salem, J., Sabouret, P. F., Funck‐Brentano, C., & Hulot, J. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12091 · Cited by 56
Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome
Utne, K. K., Dahm, A. E. A., Wik, H. S., Jelsness‐Jørgensen, L., Sandset, P. M., & Ghanima, W. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.013 · Cited by 50
Wolfe, Z., Khan, S. U., Nasir, F., Subramanian, C. R., & Lash, B. W. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14131 · Cited by 51
Weycker, D. A., Li, X., Wygant, G. D., Lee, T. T. H., Hamilton, M., Luo, X., Vo, L., Mardekian, J., Pan, X., Burns, L. C., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1673689 · Cited by 52
Sert, S. M., Mutlu, B., Kocakaya, D., Deniz, K., Halil, A., Erdoğan, O., & Yıldızeli, B. (2020) · Pulmonary Circulation · doi:10.1177/2045894019873545 · Cited by 49
Awada, H. K., Voso, M. T., Guglielmelli, P., & Gurnari, C. (2020) · Cancers · doi:10.3390/cancers12071746 · Cited by 46
“4 per 100 patients-year) is comparable to non-ET patients under VKA treatment [79,85].”
ResultAnticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
Thaler, J., Pabinger, I., & Ay, C. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00030 · Cited by 58
“Edoxaban was investigated in the Hokusai-VTE study, a double-blind, double-dummy study that compared edoxaban to standard treatment (11).”
MethodBurness, C. B., & Perry, C. M. (2014) · Drugs · doi:10.1007/s40265-013-0174-4 · Cited by 50
“Once-daily edoxaban tosylate, following initial heparin treatment, was noninferior to standard therapy (warfarin) with respect to the incidence of recurrent symptomatic VTE and was associated with significantly less bleeding in 4,921 patients with DVT and 3,319 patients with PE in the Edoxaban Hokusai-VTE Study [89].”
BackgroundMajor Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure
Raccah, B. H., Perlman, A., Danenberg, H. D., Pollak, A., Muszkat, M., & Matok, I. (2016) · CHEST Journal · doi:10.1016/j.chest.2015.12.029 · Cited by 51
“The primary endpoint of the present analysis was defined as intracranial hemorrhage and major bleeding or, when reported, the combination of major bleeding with clinically relevant nonmajor bleeding.(16-18,22,28)”
BackgroundSebastian, T., Hakki, L. O., Spirk, D., Baumann, F. A., Périard, D., Banyai, M., Spescha, R. S., Kucher, N., & Engelberger, R. P. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.10.027 · Cited by 46
Cohen, A. T., Sah, J., Dhamane, A. D., Lee, T. T. H., Rosenblatt, L. C., Hlavacek, P., Emir, B., Delinger, R. L., Yüce, H., & Luo, X. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1740254 · Cited by 50
Peri-procedural management of patients taking oral anticoagulants
Daniels, P. R. (2015) · BMJ · doi:10.1136/bmj.h2391 · Cited by 47
Basics of diagnosis and treatment of venous thromboembolism
Cox, C., & Roberts, L. N. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.01.009 · Cited by 50
Douxfils, J., Tamigniau, A., Châtelain, B., Goffinet, C., Dogné, J.-M., & Mullier, F. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-24 · Cited by 54
“Effectively, they were found at least as efficacious, if not better, than warfarin in the setting of stroke prevention in adult patients with non-valvular atrial fibrillation (NVAF) [1-4] and in the treatment and the secondary prevention of venous thromboembolism [5-9].”
BackgroundWells, P. S., Segers, A. E. M., Ageno, W., Brekelmans, M. P. A., Cohen, A. T., Meyer, G., GROSSO, M. A., Raskob, G., Weitz, J. I., Zhang, G., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0244 · Cited by 54
Vandell, A. G., Lee, J., Shi, M., Rubets, I., Brown, K. S., & Walker, J. R. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.82 · Cited by 45
Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
Aronis, K. N., & Hylek, E. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007338 · Cited by 48
“Hokusai-VTE compared edoxaban with warfarin in patients with VTE and had the highest enrollment of patients with cancer (n=771).(25) In prespecified and post hoc subgroup analysis of Hokusai-VTE in patients with cancer, edoxaban failed to meet the noninferiority margin in preventing recurrent VTE.”
Radadiya, D. K., Devani, K., Brahmbhatt, B. S., & Reddy, C. M. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002035 · Cited by 55
Houghton, D. E., Vlazny, D. T., Casanegra, A. I., Brunton, N. E., Froehling, D. A., Meverden, R. A., Hodge, D. O., Peterson, L. G., McBane, R. D., & Wysokiński, W. E. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.026 · Cited by 46
“in the treatment and secondary prevention of venous thromboembolism (VTE) (1-6) but since patients with cancer-associated VTE (Ca-VTE) are at increased risk for both recurrent VTE and bleeding new studies specifically designated for Ca-VTE were necessary.”
BackgroundKang, N., & Sobieraj, D. M. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.03.035 · Cited by 52
Eerenberg, E. S., Cohen, A. T., Middeldorp, S., Raskob, G. E., Buller, H. R., Bleker, S. M., & Brekelmans, M. P. A. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0946 · Cited by 47
“35 (19) 18 (10) 13 (7) 2 (1) 2 (1) 59 (33) 10 (6) 5 (3) 10 (6) 17 (9) 8 (4) 14 (8) 5 (3) 17 (9)”
Sex matters: Practice 5P's when treating young women with venous thromboembolism
Bistervels, I. M., Scheres, L. J. J., Hamulyák, E. N., & Middeldorp, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14549 · Cited by 49
An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
Mujer, M. T. P., Rai, M. P., Atti, V., Dimaandal, I., Chan, A. S., Shrotriya, S., Gundabolu, K., & Dhakal, P. (2020) · Advances in Hematology · doi:10.1155/2020/7636104 · Cited by 50
“[11] +e Hokusai-VTE Investigators, “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism,” New England Journal of Medicine, vol.”
BackgroundDirect Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus
Willeford, A., Zhu, W., Stevens, C., & Thomas, I. C. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020975111 · Cited by 46
A rapid pro-hemostatic approach to overcome direct oral anticoagulants
Thalji, N. K., Ivanciu, L., Davidson, R., Gimotty, P. A., Krishnaswamy, S., & Camire, R. M. (2016) · Nature Medicine · doi:10.1038/nm.4149 · Cited by 43
Ex vivo reversal of the anticoagulant effects of edoxaban
Halim, A., Samama, M. M., & Mendell, J. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.07.036 · Cited by 43
“Edoxaban is a novel, oral, once-daily direct inhibitor of both free and bound activated factor X (FXa) [1], which has been evaluated for stroke prevention in patients with non-valvular atrial fibrillation [2] and for the treatment and secondary prevention of recurrent thromboembolism in patients with acute symptomatic…”
BackgroundCancer-Associated Thrombosis: Pathophysiology, Laboratory Assessment, and Current Guidelines
Tsantes, A. G., Petrou, E., Tsante, K. A., Sokou, R., Frantzeskaki, F. G., Domouchtsidou, A., Chaldoupis, A. E., Fortis, S. P., Piovani, D., Nikolopoulos, G. K., et al. (2024) · Cancers · doi:10.3390/cancers16112082 · Cited by 63
“High risk ( ≥ 3 points): prophylaxis indicated.”
Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants
Ageno, W., Caramelli, B., Donadini, M. P., Girardi, L., & Riva, N. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00281-3 · Cited by 56
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.